Page 10 of 11 – SEC Filing
| CUSIP No. 00847L100 | SCHEDULE 13D | Page 10 of 11 |
(c) Except as previously reported or as set forth in this Item 5(c), or otherwise herein, to the knowledge of the Reporting Persons with respect to the persons named in response to Item 5(a), none of the persons named in response to Item 5(a) has effected any transactions in the Common Stock during the past 60 days.
Between August 9, 2016 and December 19, 2017, Aisling sold the following Shares set forth in the table below in open market transactions:
| Date | Shares Sold | Price Per Share |
| 8/29/2016 | 5,000 | $7.54 |
| 8/30/2016 | 11,200 | $7.31 |
| 8/31/2016 | 6,900 | $7.24 |
| 9/1/2016 | 115,198 | $7.45 |
| 9/2/2016 | 9,703 | $7.28 |
| 9/6/2016 | 11,777 | $7.09 |
| 9/7/2016 | 7,426 | $7.09 |
| 9/8/2016 | 32,796 | $7.04 |
| 9/20/2016 | 3,138 | $7.41 |
| 9/21/2016 | 7,777 | $7.43 |
| 9/22/2016 | 4,220 | $7.30 |
| 9/23/2016 | 4,364 | $7.20 |
| 9/26/2016 | 32,843 | $7.23 |
| 9/27/2016 | 25,253 | $7.35 |
| 9/28/2016 | 6,023 | $7.30 |
| 9/29/2016 | 5,000 | $7.13 |
| 9/30/2016 | 19,724 | $7.01 |
| 10/3/2016 | 12,518 | $7.16 |
| 10/4/2016 | 12,671 | $7.06 |
| 10/5/2016 | 14,168 | $7.07 |
| 10/6/2016 | 52,301 | $7.18 |
| 10/12/2016 | 11,600 | $7.79 |
| 10/17/2016 | 6,547 | $7.53 |
| 10/18/2016 | 12,301 | $7.23 |
| 10/19/2016 | 19,821 | $7.06 |
| 10/20/2016 | 7,574 | $7.00 |
| 10/21/2016 | 10,391 | $7.01 |
| 10/24/2016 | 2,854 | $7.00 |
| 10/25/2016 | 8,683 | $7.17 |
| 10/25/2016 | 250,000 | $7.17 |
| 11/8/2016 | 12,140 | $7.66 |
| 11/9/2016 | 4,932 | $7.36 |
| 11/11/2016 | 5,918 | $7.20 |
| 11/14/2016 | 3,789 | $7.21 |
| 11/15/2016 | 2,710 | $7.20 |
| 11/16/2016 | 400 | $7.21 |
| 11/17/2016 | 4,211 | $7.21 |
| 11/18/2016 | 14,873 | $7.20 |
| 11/21/2016 | 200 | $7.20 |
| 12/18/2017 | 300,000 | $4.62 |
| 12/19/2017 | 200,000 | $4.61 |
(d) The partners of Aisling have the right to participate in the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock held for the account of Aisling in accordance with their ownership interests in Aisling.
(e) As of December 18, 2017, immediately following certain transactions described in Item 5(c) above, the Reporting Persons ceased to beneficially own more than 5% of the Common Stock of the Issuer.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
No material change.
Item 7. Material to be Filed as Exhibits.
| Exhibit 2: | Fifth Amended and Restated Registration Rights Agreement, dated as of July 18, 2012, by and among the Issuer and the parties listed therein, as modified by the Amendment to Registration Rights Agreement, dated as of May 5, 2014, by and among the Issuer and the parties listed therein (incorporated herein by reference to Exhibit 4.2 to the Form S-1/A filed by the Issuer on May 9, 2014 (File No. 333-194621))(previously filed). | |
| Exhibit 3: | Joint Filing Agreement dated as of May 30, 2014, as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (previously filed). | |
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Follow Agile Therapeutics Inc (NASDAQ:AGRX)
Receive real-time insider trading and news alerts
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
